| Price | 28.825 on 10-12-2025 at 12:30:03 |
|---|---|
| Change | -0.05 -0.17% |
| Buy | 30.25 |
| Sell | 27.40 |
| Last Trade: | Sell 3,000.00 at 28.75 |
| Day's Volume: | 3,000 |
| Last Close: | 28.875 |
| Open: | 28.20 |
| ISIN: | SE0015244520 |
| Day's Range | 26.80 - 28.825 |
| 52wk Range: | 21.95 - 42.775 |
| Market Capitalisation: | - |
| VWAP: | 28.75 |
| Shares in Issue: | 65.80m |
Bioinvent Inter (0H22) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 3,000 | 28.75 | SI Trade |
09:48:47 - 10-Dec-25 |
| Sell* | 600 | 29.45 | SI Trade |
13:43:29 - 09-Dec-25 |
| Unknown* | 1,016 | 30.35617 | Currency Conversion Negotiated Trade |
08:35:44 - 08-Dec-25 |
| Buy* | 4,444 | 28.35 | SI Trade |
10:16:58 - 04-Dec-25 |
| Buy* | 120 | 27.55 | SI Trade |
13:56:06 - 02-Dec-25 |
| Sell* | 149 | 28.65 | SI Trade |
15:18:14 - 28-Nov-25 |
| Sell* | 467 | 28.70 | SI Trade |
13:52:09 - 26-Nov-25 |
| Sell* | 101 | 29.60 | SI Trade |
11:05:16 - 25-Nov-25 |
| Sell* | 101 | 29.60 | SI Trade |
11:05:16 - 25-Nov-25 |
| Sell* | 388 | 29.60 | SI Trade |
15:28:46 - 21-Nov-25 |
Bioinvent Inter (0H22) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 8th Dec 2025 1:00 pm | MFN | BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm | MFN | BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |
